• SELECT SITE CURRENCY
Select a currency for use throughout the site
U.S. Antiarthritis Markets
Frost & Sullivan, February 2001
Market Leaders Focus on Technology
Recent advances in drug discovery by biotechnology companies have jump-started
languishing antiarthritis markets. Biotechnology industry participants
long ago recognized the many untapped opportunities in the arthritis market.
Now, they are at the forefront with immune system discoveries works and
innovations for treatments and possibly prevention of rheumatoid arthritis
This Frost & Sullivan research evaluates the current state of the U.S. prescription
arthritis market. It forecasts revenues, growth, and product pricing in
three major segments, and covers present and future therapies. Market drivers,
restraints, demand analysis and more empowers your success.
Marketing Innovations Key to Maximizing Return
Research shows that of an estimated 43 million people afflicted with arthritis
in the U.S., only about eight percent are receiving treatment. Successful manufacturers
of antiarthritic treatments must educate users and the healthcare
industry about new drug discoveries through aggressive marketing campaigns
to become market winners.
The growing percentage of the U.S. population suffering from arthritis can
make demand skyrocket for antiarthritic drugs, states the author of this
New Opportunities with Accelerated Market Acceptance
Antiarthritic markets are expected to grow with the introduction of new
drugs and treatments. New disease-modifying anti-rheumatic drugs (DMARDs)
are the first of their kind in a generation.
Most of the DMARDs have been available in the market for decades, some
for 70 years, in the treatment of RA, states the author. This market got a
new life with the launch of products which gained immediate acceptance.
Arthritis is one of the most prevalent diseases in America. This Frost &
Sullivan research offers an in-depth analysis of the U.S. antiarthritis markets. It
highlights the treatments available for RA, the most debilitating form of arthritis,
and reports on new treatments and drug development which hold the key
to market's future.
This Frost & Sullivan report presents a clear look at the opportunities and
threats in individual market areas, by providing your company with tools necessary
to excel in the U.S. Antiarthritis Markets.
- Introducing the Market Engineering Consulting Report
- Executive Summary
- Introduction to the U.S. Prescription Arthritis Market
- Objectives and Purpose
- Report Scope and Segmentation
- Report Structure
- Current Treatments